Earnings call transcript: DiaSorin Q4 2025 shows stable performance amid challenges

DiaSorin reported 2025 revenues just shy of €1.2bn, up ~1% YoY, with adjusted EBITDA €394m (33% margin) and adjusted net income €223m, down 6% YoY due to higher interest/taxes and a ~€34m FX headwind. Management guides 2026 revenue growth of 5–6% at constant FX and an adjusted EBITDA margin of 32–33%, highlights a commercial launch of the LIAISON NES platform on April 1, 2026, and flags risks from USD depreciation (c. €6–7m revenue impact per cent), China VBP (~€5–8m headwind), tariffs (potential ~€4m upside) and Middle East conflict/logistics. Net debt closed at €580m and management expects structural resilience but a back‑loaded 2026 driven by product timing and a weak early flu season.

Analysis

Distribution partners and companies that monetize consumable streams (think large US distributors and hospital-focused suppliers) are the biggest asymmetric winners from a successful commercial roll‑out: exclusives and route-to-market scale convert a one‑time instrument placement into multi‑year consumable annuity with much higher IRR than OEMs’ direct sales. The tariff refund process — effectively a discrete 30–60 day operational catalyst for importers — creates a binary near‑term cashflow and margin shock that investors tend to underweight because it lives in the operational, not headline, P&L.

Downside pressure concentrates on commodity-focused manufacturers and anyone with large China/price‑controlled exposure; shifting to specialty assays raises gross margin potential but lengthens payback and increases regulatory execution risk. Raw‑material inflation and logistics rerouting (loss of key transshipment hubs) are low‑frequency, high‑impact tail risks that would compress gross margins by several hundred basis points within months if sustained.

The commercial rollout of new small‑form platforms is likely to be back‑loaded and yield negative margin dilution in the first 6–12 months; the alpha will come from which distributors convert early adopters into recurring users, not from unit placements alone. FX remains the single biggest cross‑cutting swing factor: a few cents’ move in USD/EUR materially changes top‑line and EBITDA assumptions for European med‑techs within a single year, so directional exposure should be paired with currency hedges or relative trades rather than outright conviction longs.

Key Decisions for Investors

• Long MCK (McKesson): buy MCK shares or a 6–12m call spread (e.g., buy 1x ATM call, sell 1x 20–30% OTM call) after the next two quarterly updates — Rationale: capture distribution/consumable annuity; target 20–35% upside, max loss = premium (~100% of option spend) if exclusivity/rollout stalls.
• Pair trade — Long MCK / Short LMNX (Luminex) for 6–12 months: equal notional exposure to benefit from distributor share capture vs legacy multiplex incumbents; expected pair return 25–40% if adoption skews to distributor channel, risk: 15–25% if broad market recovery lifts both.
• Protective short on QGEN (Qiagen) via a put spread (9–12m): buy modest OTM puts and sell lower‑strike puts to limit premium (e.g., 40/30% OTM put spread sized to 1–2% portfolio risk) — thesis: TB/multiplex pricing competition and local incumbents could compress ASPs; payoff if shares fall 25–50%.
• Portfolio-level action: reduce outright EUR‑denominated med‑tech long exposure by 10–20% and replace with relative/paired trades above, or overlay a EURUSD forward call (3–12m) sized to offset ~60% USD revenue exposure — rationale: hedge the single largest macro swing (FX) that moves EBITDA materially within months.